Unique ID issued by UMIN | UMIN000034799 |
---|---|
Receipt number | R000039667 |
Scientific Title | Surgical outcomes in patients who received presurgical treatment with pazopanib for advanced renal cell carcinoma with inferior vena cava tumor thrombus; a historical control study |
Date of disclosure of the study information | 2018/12/01 |
Last modified on | 2020/09/10 08:46:15 |
Surgical outcomes in patients who received presurgical treatment with pazopanib for advanced renal cell carcinoma with inferior vena cava tumor thrombus; a historical control study
Surgical outcomes in patients who received presurgical treatment with pazopanib for advanced renal cell carcinoma with inferior vena cava tumor thrombus; a historical control study
Surgical outcomes in patients who received presurgical treatment with pazopanib for advanced renal cell carcinoma with inferior vena cava tumor thrombus; a historical control study
Surgical outcomes in patients who received presurgical treatment with pazopanib for advanced renal cell carcinoma with inferior vena cava tumor thrombus; a historical control study
Japan |
Renal cell carcinoma
Urology |
Malignancy
YES
We evaluate improvement of surgical outcome of resection both tumor and thrombus by presurgical treatment with pazopanib in patients with advanced renal cell carcinoma (RCC) with inferior vena cava tumor thrombus.
Safety
bleeding volume in surgery
-Improvement of surgical invasion: Outcome of change from surgical procedure expected before surgery to minimally invasive surgical procedure due to tumor reduction.
-Operation time
-Grade 3 or higher complications
-Reduction in the level of tumor embolism according to the classification of Mayo clinic
-Reduction rate of primary tumor and metastatic lesion.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
12 weeks oral administration of pazopanib.
Surgical excision of tumor and thrombus within 7 days and 21 days from the end date of pazopanib administration
20 | years-old | <= |
Not applicable |
Male and Female
1.Renal cell carcinoma with tumor thrombus
2.Tumor thrombus which reach Inferior vena cava
3.Written informed consent
1.Patients who did not participate in this study
2.Patients who participated in other clinical trials within 4 months.
3.Performance Status> 3
4.AST,ALT> 3.0*upper limit of normal range(ULN), or total Bil> 2.0*ULN
5.Patients who receive treatment of other cancer
25
1st name | |
Middle name | |
Last name | Tomoaki Terakawa |
Kobe University Graduate School of Medicine
Urology
7-5-2 Kusunoki-cho, Chuo-ku, Kobe City, Hyogo Prefecture, JAPAN,
0783826155
daatera0804@yahoo.co.jp
1st name | |
Middle name | |
Last name | Yasuyoshi Okamura |
Kobe university Graduate School of Medicine
Urology
7-5-2 Kusunoki-cho, Chuo-ku, Kobe City, Hyogo Prefecture, JAPAN,
0783826155
dfgky008@gmail.com
Kobe university Graduate School of Medicine Division of Urology
Kobe university Graduate School of Medicine
Division of Urology
Self funding
NO
神戸大学医学部付属病院
2018 | Year | 12 | Month | 01 | Day |
Unpublished
Completed
2018 | Year | 11 | Month | 01 | Day |
2019 | Year | 05 | Month | 24 | Day |
2018 | Year | 12 | Month | 01 | Day |
2025 | Year | 03 | Month | 31 | Day |
2018 | Year | 11 | Month | 07 | Day |
2020 | Year | 09 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039667
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |